To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Critical Care ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Deep vein thrombosis and its prevention in critically ill patients.Arch Intern Med. 2001; 161: 1268-1269
- Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis.Crit Care Med. 2002; 30: 771-774
- Deep venous thrombosis in medical-surgical ICU patients: prevalence, incidence and risk factors [abstract].Crit Care. 2003; 7: S54
- Prevention of venous thromboembolism.Chest. 2001; 119: 132S-175S
- Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest. 2004; 126: 338S-400S
Arnold D.M., Warkentin T.E. Thrombocytopenia and thrombocytosis in critical care. In: Wilson W.C., Grande C.M., editors. Trauma, resuscitation, anesthesia, and critical care. New York: Marcel Dekker, Inc., in press
- Thrombocytopenia in medical-surgical ICU patients [abstract].Crit Care. 2004; 8: A125
- Thrombocytopenia in the intensive care unit.Chest. 1993; 104: 1243-1247
- Thrombocytopenia in intensive care patients: a comprehensive analysis of risk factors in 314 patients.Ann Pharmacother. 1997; 29: 835-842
- Incidence and risk factors of thrombocytopenia in critically ill trauma patients.Ann Pharmacother. 1997; 31: 285-289
- Risk markers for thrombocytopenia in critically ill patients: a prospective analysis.Pharmacotherapy. 2002; 22: 803-813
- Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome.Crit Care Med. 2002; 30: 1765-1771
- Coagulopathy of sepsis.Thromb Haemost. 2004; 91: 213-224
- Pseudo-heparin-induced thrombocytopenia.in: Warkentin T.E. Greinacher A. Heparin-induced thrombocytopenia. 3rd edition. Marcel Dekker, Inc., New York2004: 313-334
- Thrombocytopenia due to acute venous thromboembolism and its role in expanding the differential diagnosis of heparin-induced thrombocytopenia.Am J Hematol. 2004; 76: 69-73
- Heparin-induced thrombocytopenia: pathogenesis and management.Br J Haematol. 2003; 121: 535-555
- Plasma P-selectin is increased in thrombotic consumptive platelet disorders.Blood. 1994; 83: 1535-1541
- The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.Ann Intern Med. 1997; 127: 804-812
- An overview of the heparin-induced thrombocytopenia syndrome.Semin Thromb Hemost. 2004; 30: 273-283
- Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express cells to express tissue factor and secrete interleukin-8.Blood. 2001; 98: 1252-1254
- Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban.Thromb Res. 2003; 110: 73-82
- Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody.Blood. 2002; 99: 1230-1236
- Heparin-induced thrombocytopenia: laboratory studies.Blood. 1988; 72: 925-930
- Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia.Blood. 1994; 84: 3691-3699
- Impact of the patient population on the risk for heparin-induced thrombocytopenia.Blood. 2000; 96: 1703-1708
- Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia.J Lab Clin Med. 1992; 120: 371-379
- Laboratory testing for HIT antibodies: how much class do we need?.Blood. 2004; 104: 825a
- Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation.Br J Haematol. 2000; 109: 336-341
- Increased expression of platelet IgG Fc receptors in immune heparin-induced thrombocytopenia.Blood. 1993; 81: 988-993
- The platelet Fc receptor in heparin-induced thrombocytopenia.in: Warkentin T.E. Greinacher A. Heparin-induced thrombocytopenia. 3rd edition. Marcel Dekker, Inc., New York2004: 223-250
- The homozygous FcγRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin/platelet factor 4 complexes.Blood. 2004; 104: 2791-2793
- Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells.Thromb Haemost. 1998; 80: 326-331
- Clinical picture of heparin-induced thrombocytopenia.in: Warkentin T.E. Greinacher A. Heparin-induced thrombocytopenia. 3rd edition. Marcel Dekker, Inc., New York2004: 53-106
- Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.N Engl J Med. 1995; 332: 1330-1335
- An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients.Arch Intern Med. 2003; 163: 2518-2524
- Temporal aspects of heparin-induced thrombocytopenia.N Engl J Med. 2001; 344: 1286-1292
- Laboratory diagnosis of immune heparin-induced thrombocytopenia.Curr Hematol Rep. 2003; 2: 148-157
- Preliminary evaluation of a clinical scoring system for estimating the pretest probability of heparin-induced thrombocytopenia: the “4 T's” [abstract].Blood. 2003; 102: 535a
- A 14-year study of heparin-induced thrombocytopenia.Am J Med. 1996; 101: 502-507
- Lack of value of clinical predictors of heparin induced thrombocytopenia (HIT) in complex patients.Blood. 2004; 104 ([Abstract]): 569a
- Adrenal hemorrhage: a 25-year experience at the Mayo Clinic.Mayo Clin Proc. 2001; 76: 161-168
- Bilateral massive adrenal hemorrhage. Assessment of putative risk factors by the case-control method.Medicine (Baltimore). 2001; 80: 45-53
- Laboratory testing for heparin-induced thrombocytopenia.in: Warkentin T.E. Greinacher A. Heparin-induced thrombocytopenia. 3rd edition. Marcel Dekker, Inc., New York2004: 271-311
- Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay.Transfusion. 1996; 34: 381-385
- Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis.J Lab Clin Med. 2001; 138: 22-31
- Determination of heparin–platelet factor 4–IgG antibodies improves diagnosis of heparin-induced thrombocytopenia.Br J Haematol. 2001; 113: 886-890
- Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera form heparin-induced thrombocytopenia patients.Blood. 1998; 91: 549-554
- Frequency of heparin-induced thrombocytopenia.in: Warkentin T.E. Greinacher A. Heparin-induced thrombocytopenia. 3rd edition. Marcel Dekker, Inc., New York2004: 107-148
- Heparin-induced thrombocytopenia (HIT) in orthopedic patients: a prospective cohort trial comparing UFH and LMWH [abstract].Ann Hematol. 2000; 79: A92
- Heparin-induced thrombocytopenia and cardiac surgery.Ann Thorac Surg. 2003; 76: 2121-2131
- Antibodies to platelet factor 4–heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin. Clinical implications for heparin-induced thrombocytopenia.Circulation. 1999; 99: 2530-2536
- Changes in the platelet count after cardiopulmonary bypass can efficiently predict the development of pathogenic heparin-dependent antibodies [abstract].Blood. 2002; 100: 16a
- Heparin-induced thrombocytopenia: recognition, treatment, and prevention. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest. 2004; 126: 311S-337S
- The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study.Blood. 2003; 101: 2955-2959
- Frequency of heparin-induced thrombocytopenia in critical care patients.Pharmacotherapy. 2003; 23: 745-753
- Heparin-induced thrombocytopenia in medical-surgical ICU patients [abstract].Crit Care Med. 2004; 31: A73
- Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.Chest. 1999; 115: 1616-1620
- Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia.Am J Med. 1999; 106: 629-635
- Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies.Thromb Res. 2003; 108: 49-55
- Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis.Mol Cell Biochem. 2004; 258: 163-170
- Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin.Br J Haematol. 2002; 118: 1137-1142
- Utilization of venous thromboembolism prophylaxis in the medical intensive care unit.Chest. 1994; 106: 13-14
- Venous thromboembolic disease: an observational study in medical-surgical intensive care unit patients.J Crit Care. 2000; 15: 127-132
- Utilization of venous thromboembolism prophylaxis in a medical-surgical ICU.Chest. 1998; 113: 162-164
- Prevention of venous thromboembolism in critically ill surgery patients: a cross-sectional study.J Crit Care. 2001; 16: 161-166
- Venous thromboembolism and its prevention in critical care.J Crit Care. 2002; 17: 95-104
- Prevention of venous thromboembolism: guidelines compiled in accordance with the scientific evidence.Int Angiol. 2001; 20: 1-37
- Prevention of venous thromboembolism (VTE) in critically ill medical patients: a Franco-Canadian cross-sectional study.J Crit Care. 2003; 18: 228-237
- Prevention and diagnosis of venous thromboembolism in critically ill patients: a Canadian survey.Crit Care. 2001; 5: 336-342
- A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma.N Engl J Med. 1996; 335: 701-707
- High risk of the critically ill for venous thromboembolism.Crit Care Med. 1982; 10: 448-450
- Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France.Am J Respir Crit Care Med. 2000; 161: 1109-1114
- Prophylaxis for thromboembolism in critical care trial: a pilot study [abstract].Am J Respir Crit Care Med. 2004; 169: A666
Article info
Footnotes
Supported by Heart and Stroke Foundation of Ontario grant T-5207 (T.E.W.) and by the Canadian Institutes for Health Research (D.J.C.).
Identification
Copyright
© 2005 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
